Primary Care Study With Chondroitin Sulfate and Glucosamine Hydrochloride in Hand Osteoarhritis

NCT ID: NCT02823548

Last Updated: 2016-11-11

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 330 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-08-31
• Study Completion Date: 2017-07-31

Brief Summary

PICASSO has been designed to demonstrate that combination therapy with CS/GH has superior efficacy compared to placebo in pain reduction (average score reduction in Huskisson's 0 to 100 mm Visual Analogue Scale) from baseline to 6 months of treatment in patients with symptomatic hand osteoarthritis.

Conditions

Hand Osteoarthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Droglican

Patients take one sacchet of Droglican (Chondroitin Sulfate 1,500mg + Glucosamine Hydrochloride 1,200mg) Once a day during 6 months.

Group Type: EXPERIMENTAL

Droglican

Intervention Type: DRUG

Chondroitin Sulfate 1,200mg + Glucosamine Hydrochloride 1,500mg

Placebo

Patients take one sacchet of Placebo once a day during 6 months.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo

Interventions

Droglican

Chondroitin Sulfate 1,200mg + Glucosamine Hydrochloride 1,500mg

Intervention Type: DRUG

Placebo

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Men and women ≥ 40 years of age;

2. Clinical diagnosis of hand osteoarthritis according to ACR criteria;

3. Patients who have pain and deformities in at least 2 interphalangeal joints of the studied hand;

4. Patients with simple standard anteroposterior X-ray of both hands obtained within the 6 months prior to screening;

5. Patients with radiological evidence of hand osteoarthritis grade 2-3 according to the Kellgren-Lawrence radiological scale. Patients must present radiological involvement of at least 2 interphalangeal joints of the studied hand, with or without rhizarthrosis;

6. Patients who have had pain in the studied hand most of the days of the month prior to the screening visit;

7. Patients with hand pain ≥ 45 mm on Huskisson's Visual Analogue Scale at the screening visit;

8. Patients who present a Functional Index of Hand Osteoarthritis (FIHOA) score ≥ 6 at the screening visit;

9. Women of childbearing age (women whose last menstrual period was more than one year before study enrolment and those who have had tubal ligation or a hysterectomy performed are excluded) must have obtained a negative result for the pregnancy test conducted in the screening phase and must agree to use a medically acceptable contraceptive method throughout the duration of the study. Men participating in the study must also agree to use a medically acceptable contraceptive if they have intercourse with women of childbearing age;

10. Patients must have a sufficient level of cognition to allow for proper communication and cooperation with all tests and examinations required in the protocol;

11. Patients who have been clearly informed of the methods and limitations of the study and agree to sign the informed consent form prior to the conduct of any study procedure and after they;

12. Patients who are not participating in another clinical trial;

13. Patients who agree to respect the protocol, attending visits related to the study;

Exclusion Criteria

1. Patients with isolated unilateral or bilateral rhizarthrosis only and/or radiological evidence of presence of erosive hand osteoarthritis (having just one erosive joint leads to classifying the patient as erosive).

2. Patients with a known allergy to CS or GH;

3. Patients with a seafood allergy;

4. Patients with a history of intolerance to paracetamol;

5. Patients with active malignancy of any type or with a history of malignancy in the last five years;

6. Patients who, in the investigator's judgement, do not have significant clinical alterations in their physical examination and laboratory parameters;

7. History of any condition which, in the investigator's opinion, could lead to misinterpretation of the study results or could pose an additional risk to the patient;

8. Concurrent articular rheumatism (history and/or current presence of signs) that could give rise to an erroneous interpretation of the efficacy on pain or which interfere in its assessment, such as carpal tunnel syndrome, Guyon's canal syndrome (involvement of cubital nervous), flexor tenosynovitis, trigger finger, chondrocalcinosis, , aseptic osteonecrosis, gout, septic arthritis, ochronosis, acromegaly, haemochromatosis, Wilson's disease, osteochondromatosis, rheumatoid arthritis, ankilosing spondylitis, psoriasis, inflammatory bowel disease, connective tissue disease, vasculitis, diabetic neuropathy, post-traumatic osteoarthritis of the finger;

9. Pain in other parts of the body more intense than in the hand, which could interfere with the assessment of the joint index;

10. Patients with fibromyalgia;

11. Patients with surgery scheduled during the clinical trial period;

12. Patients with important diseases or processes, such as psychological or psychiatric disorders or drug consumption which, in the investigator's opinion, is likely to alter the progress of the osteoarthritis or the patient's ability to complete the study;

13. Patients with poorly controlled diabetes mellitus defined as a level of haemoglobin A1c> 8%;

14. Patients with poorly controlled hypertension (sustained systolic blood pressure ≥160 mm Hg or sustained diastolic blood pressure ≥100 mm Hg);

15. Patients with active acute or chronic infections that require antibiotic treatment, or serious fungal or viral infections (for example, hepatitis, herpes zoster, HIV positive);

16. Patients with chronic liver or kidney disease, defined by AST or ALT levels > 2 times the upper limit of normal (ULN) or blood urea nitrogen (BUN) or serum creatinine levels > 2 times the ULN at the inclusion visit;

17. Patients with a history of alcohol or drug consumption or abuse in the last 3 years;

18. Patients who have received any investigational drug in the 30 days prior to the screening visit;

19. Women who are breastfeeding;

• Patients who are receiving lithium carbonate, phenytoin or anti-coagulants, such as warfarin (with the exception of ASA up to a maximum daily dose of 100 mg);

Patients should complete the following washout periods to treatments prior to inclusion visit:

• 6 months for intra-articular hyaluronic acid in hands;
• 3 months for articular lavage, glucosamine, CS, diacerein or nutraceuticals;
• 1 month for corticosteroids(oral, injectable), topical corticosteroids for the hands, medicinal plants or homoeopathic products indicated for hand OA;
• 1 week for analgesic creams or gels for the hands (i.e. Capsaicin), oral analgesics, including opioids such as tramadol and codeine; for oral and topic NSAIDs and for oral selective COX-2 inhibitors (Coxibs); Patients are allowed to continue with ASA treatment (up to a maximum daily dose of 100 mg) for cardiovascular events prevention;
• 1 week for physical therapies such as acupuncture, electromagnetic fields, physiotherapy and paraffin baths.

• Minimum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bioiberica

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Barcelona, , Spain

Site Status: RECRUITING

Countries

Spain

Central Contacts

Marta Herrero

Role: CONTACT

Phone: +34934904908

Email: mherrero@bioiberica.com

Other Identifiers

DRO/IV-2016-ART-02

Identifier Type: -

Identifier Source: org_study_id